27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) announced topline results from Phase 3 Lavender study of trofinetide in Rett syndrome.
- The 12-week study demonstrated a statistically significant improvement over placebo for both co-primary endpoints.
- Rett syndrome is a rare genetic neurological and developmental disorder that typically affects girls.
- The Rett Syndrome Behaviour Questionnaire (RSBQ) change from baseline to week 12 was -5.1 vs. -1.7 (p=0.0175; effect size=0.37).
- The Clinical Global Impression–Improvement (CGI-I) score at week 12 was 3.5 vs. 3.8 (p=0.0030; effect size=0.47).
- The RSBQ is a caregiver assessment of the core symptoms, and the CGI-I is a global physician assessment of worsening or improving of Rett syndrome.
- Additionally, trofinetide demonstrated a statistically significant separation over placebo on the scale of communication delay. The change from baseline to week 12 was -0.1 vs. -1.1 (p=0.0064; effect size=0.43).
- Study treatment discontinuation rates related to treatment-emergent adverse events (TEAEs) were 17.2% in the trofinetide group compared to 2.1% in the placebo group.
- The most common adverse events were diarrhea (80.6% with trofinetide vs. 19.1% with placebo).
- Acadia is preparing for a pre-NDA meeting with the FDA in Q1 of 2022 and plans to submit a marketing application around mid-year 2022.
- Price Action: ACAD shares are up 14% at $22.12 during the premarket session on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!